BioSpace News Archive

Intercept Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, announced that the U.S. FDA has issued a Complete Response Letter regarding the New Drug Application for obeticholic acid for the treatment of fibrosis due to nonalcoholic steatohepatitis.

Cancer Access Partnership is expected to result in a 59 percent savings on procured cancer medicines

Zimmer Biomet Holdings, Inc. announced its second quarter earnings conference call will be webcast on Tuesday, August 4, 2020, at 8:30 a.m. ET.

Alkermes plc announced that it will begin accepting applications for its annual Alkermes Pathways Research Awards® program on July 1, 2020.

Akcea Therapeutics, Inc., a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced that Tracy Palmer Berns has joined the company as chief compliance officer.

Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced that it has been added to the broad-market Russell 3000® Index and the small-cap Russell 2000® Index as part of the Russell US Indexes annual reconstitution.

Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced the appointment of Mark G. Foletta to its Board of Directors.

Cadent Therapeutics, a clinical stage biopharmaceutical company focused on the development of therapies to improve the lives of patients with cognitive, mood, and movement disorders, announced that management will participate in the following upcoming virtual investor conferences

Orthofix Medical Inc., a global medical device company focused on musculoskeletal healing products, announced the U.S. Food and Drug Administration 510 clearance and the first patient implants of the FIREBIRD™ SI Fusion System.

Tangen Biosciences, Inc. announced that it was awarded a contract by the New York State Department of Health’s Wadsworth Center in conjunction with Health Research Inc. to develop a point-of-care device for detection of Candida auris, a “superbug” that is resistant to anti-fungal drugs and is emerging as a public health threat.